Results 141 to 150 of about 153,414 (353)

Dynamics of postnatal bone development and epiphyseal synostosis in the caprine autopod

open access: yesDevelopmental Dynamics, EarlyView.
Abstract Background Bones develop to structurally balance strength and mobility. Bone developmental dynamics are influenced by whether an animal is ambulatory at birth. Precocial species, which are ambulatory at birth, develop advanced skeletal maturity in utero and experience postnatal development under mechanical loading.
Christopher J. Panebianco   +8 more
wiley   +1 more source

The Changing Landscape of Accrual Accounting

open access: green, 2020
Robert M. Bushman   +2 more
openalex   +1 more source

Cilostazol in patients with heart failure and preserved ejection fraction—The CLIP‐HFpEF trial

open access: yesESC Heart Failure, Volume 12, Issue 2, Page 1437-1446, April 2025.
• Cilostazol is an oral PDE‐3 inhibitor that may have advantageous effects in heart failure with preserved ejection fraction (HFpEF). • Cilostazol significantly improved short‐term heart failure‐related health status scores (KCCQ‐12) and NT‐proBNP levels when compared to placebo.
Norman Aiad   +9 more
wiley   +1 more source

CO30 | Risk factor for damage accrual in primary antiphospholipid syndrome: a retrospective single-center cohort study

open access: yesItalian Journal of Medicine
Premises and Purpose of the study: Despite anticoagulant therapy, in primary antiphospholipid syndrome (PAPS), a higher rate of recurrent events occurs, leading to potentially accrued damage with a negative impact on quality of life.
doaj   +1 more source

Digital implementation strategy to increase SGLT2 inhibitor uptake in heart failure: Study design of EMAIL‐HF

open access: yesESC Heart Failure, EarlyView.
Abstract Aims The EMAIL‐HF trial aims to evaluate whether a digital guideline implementation strategy can increase and accelerate initiation of sodium‐glucose co‐transporter 2 (SGLT2) inhibitors in patients with heart failure (HF). Methods and results EMAIL‐HF is a pragmatic, registry‐based, randomized controlled trial including patients with a ...
Mariam Elmegaard   +21 more
wiley   +1 more source

Cardiometabolic outcomes with dapagliflozin after myocardial infarction by baseline ejection fraction: DAPA‐MI

open access: yesESC Heart Failure, EarlyView.
We investigated cardiometabolic outcomes in patients treated with dapagliflozin 10 mg once daily or placebo after acute myocardial infarction according to LVEF at randomisation in the registry‐based, randomised DAPA‐MI trial. Regardless of baseline LVEF, dapagliflozin resulted in significant cardiometabolic benefits versus placebo, suggesting that ...
David Erlinge   +19 more
wiley   +1 more source

Home - About - Disclaimer - Privacy